Navigation Links
Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Date:8/27/2010

SAN DIEGO, Aug. 27 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that on August 25, 2010 the Compensation Committee of the Company's Board of Directors approved the grant of inducement stock options to purchase a total of 10,000 shares of common stock to two new employees.

Both of the stock options are intended to be incentive stock options to the extent permitted by law and both have an exercise price per share equal to $4.53, the fair market value on the grant date. Each stock option vests over the course of four years, with 25% vesting on the one-year anniversary of the grant date and 1/48 of the shares vesting monthly thereafter so that all of the shares subject to the stock option shall be vested on the fourth anniversary of the grant date, subject to the new employee’s continued service relationship with the Company on each such date. Each stock option has a ten year term and is subject to the terms and conditions of the Company's 2007 Equity Incentive Award Plan and the stock option agreement pursuant to which the option is granted.

Both stock options were granted as an inducement material to the new employees entering into employment with Orexigen Therapeutics in accordance with NASDAQ listing Rule 5635(c)(4).

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company has filed an NDA with the FDA for its lead investigational product, Contrave(R). The Company's second product, Empatic(TM), has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.Orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen(R) Therapeutics Schedules May 10, 2010 Webcast Discussion of Financial Results for the First Quarter Ended March 31, 2010
2. Orexigen(R) Therapeutics Appoints Wendy Dixon, Ph.D. to Board of Directors
3. Orexigen(R) Therapeutics and Patheon Announce Exclusive Manufacturing Agreement for Contrave(R)
4. Orexigen(R) Therapeutics Announces Fourth Quarter and Year Ended December 31, 2009 Financial Results
5. Orexigen(R) Therapeutics Schedules March 9, 2010 Webcast Discussion of Financial Results for the Fourth Quarter and Year Ended December 31, 2009
6. Orexigen(R) Therapeutics Appoints Peter Honig, M.D. to Board of Directors
7. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
8. Orexigen(R) Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635
9. Orexigen(R) Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
10. Orexigen(R) Therapeutics to Speak at Lazard Capital Markets Healthcare Conference
11. Orexigen(R) Therapeutics Announces Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... 2016  Granger Diagnostics today announced immediate availability of ... infections. This test ensures discovery of ALL bacteria, ... test requires only a simple swab of the wound ... G. Bostwick , MD, Chief Medical Officer, described ... "We are excited to make available, for the ...
(Date:5/25/2016)... May 25, 2016 MedDay, a biotechnology ... that an oral presentation entitled "High doses of biotin in ... will be given by Professor Ayman Tourbah , Principal ... of the European Academy of Neurology (EAN) in ... disorders 3" will take place on Sunday, 29 May 2016 ...
(Date:5/25/2016)... May 25, 2016 ReportsnReports.com ... research report that provides an overview on therapeutic ... at various stages, therapeutics assessment by drug target, ... and molecule type, along with latest updates, and ... key players involved in the therapeutic development for ...
Breaking Medicine Technology:
(Date:5/25/2016)... , ... May 25, 2016 , ... America Walks ... Carol Reichbaum, M.S.L., M.S.P.A., of the University of Pittsburgh Graduate School of Public ... will enable Ms. Reichbaum and 24 other advocates from around the country to participate ...
(Date:5/25/2016)... , ... May 25, 2016 , ... Researchers from SUNY ... COVD Meeting for their work on visual evoked potential and human attention. The article, ... that used the Diopsys® NOVA™ ERG and VEP Vision Testing System (Diopsys, ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... demand for minimally invasive, endoscopic spine surgeries in the Montgomery County, Howard County ... patients in the Germantown office of American Spine every Monday. He will also ...
(Date:5/24/2016)... , ... May 24, 2016 , ... To better understand ... new research award to examine gender differences in lung cancer. Today, the Lung Association ... Project: Lung Cancer in Women Award, funded by the American Lung Association’s LUNG FORCE ...
(Date:5/24/2016)... ... May 24, 2016 , ... United Benefit Advisors (UBA), the ... Firm Austin & Co., Inc. Headquartered in Albany, New York, Austin & ... benefits technology, and beyond. As an employee-owned company celebrating over 160 years ...
Breaking Medicine News(10 mins):